Have stomach pain and diarrhea? UC?

You may qualify for local UC research studies.

Those who qualify may receive*:

  • Payment which varies by study up to $2,000
  • No-cost study-related care from local doctors
  • No-cost study medication

Plus, no cost to you. No health insurance or referrals are needed.

Ready to get started? Click Here.

You may qualify for local research studies!

Ulcerative Colitis (UC) is an inflammatory bowel disease that causes long-lasting irritation, swelling and sores in the colon (large intestine). If you have UC, you may have stomach pain and cramping, urgent bowel movements, and diarrhea that can be bloody. You may also feel tired or nauseous, lose weight or have fevers due to UC.

Symptoms usually develop over time, rather than suddenly and can vary, depending on the severity of inflammation and where it occurs. Some people have long periods of remission, without symptoms. But many people with UC experience a relapse, or period of time during the year when symptoms are active. These active symptoms are called flares or flare-ups.

Better treatment options are needed for people who suffer with UC. Right now, local doctors are looking for people who have UC to participate in local research studies with an investigational oral medication.

* In a clinical research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from a doctor/research team for the duration of the study. Reasonable payments will be made for participation and the length of the study may vary.

Ready to get started?

Click here.

How does it work?


Tell us a little bit about yourself


Answer some questions about your health


We will connect you to available studies in your area

Just takes a few minutes


AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.